Peter Lederman in Second Bout With COVID-19

I read the writeup on the CytoDyn website and Leronimab seems to have some efficacy against HIV and some cancers.  The trial in the Philippines would seem to have little rationale other than the partial overlap in disease mechanisms among viral infections.  In fact, there is an entire paragraph explaining CytoDyn's use of optimistic terminology in the writeup which reads as a statement saying "don't read more into the data than there really is".  So, like glupson, I too hope that the drug is effective against COVID-19 but, thus far, there isn't much evidence that that is the case.

You took out of context the fact the FDA trial was with 2 doses rather than the 4 doses recommended by the manufacturer..
Mis reading the user manual when setting up a phono cartridge could lead to a poor endpoint. Endpoint for now. Tom

Not sure if you're referring to my comment.  I reported what CytoDyne said on their site, not from a trial.

The FDA calls this “data dredging”. If the drug or vaccine doesn’t meet the stated criteria for success, you find another way to make it sound good by sifting the data. It is a regulatory no-no, but may work for the lay press. Maybe it helps the stock price. 

Theaudiotweak, why do you assume the paranoid view? Maybe the truth is that this drug is not effective in severe covid, and the FDA would be doing the right thing based on real data not to grant it an EUA, much less a bona fide  license. Seems to me like the sponsor is just grasping at straws, trying to find some use for this drug that was originally developed to treat HIV, and apparently didn’t make much of a mark in that area either. Their idea is only to make money.